Recently Featured

EMA Recommends Authorisation of First Veterinary Vaccine Using RNA Technology

April 19, 2026
The European Medicines Agency (EMA) has recommended granting marketing authorisation for Nobivac NXT HCPChFeLV, marking a significant milestone as the first veterinary vaccine utilizing RNA technology. This innovative vaccine is designed to protect cats from several common infectious diseases, addressing a critical need in veterinary medicine. The endorsement by EMA underscores a growing trend towards…

Kailera Therapeutics Raises $625 Million in Record Biotech IPO

April 19, 2026
Kailera Therapeutics has achieved a significant milestone in the biotech sector by raising $625 million through its initial public offering (IPO), setting a new record that surpasses the previous benchmark established by Moderna in 2018, which was $604 million. This substantial capital influx underscores the growing investor confidence in biotech innovations and the potential for…

Five Pharma CEOs Join the $30 Million Club with Notable Pay Hikes in 2025

April 19, 2026
Several of pharma’s top leaders scored large pay bumps last year, including two new chiefs who joined the “$30 million club.” This significant increase in compensation reflects a broader trend within the industry, where executive pay is increasingly tied to company performance and shareholder returns. As the pharmaceutical sector continues to navigate complex regulatory landscapes…

FDA’s Accelerated Approval Pathway Needs Stronger Transparency, Evidence Standards: ICER

April 19, 2026
The FDA must enhance the evidence requirements for drug approvals under its accelerated pathway, while also increasing transparency regarding these regulatory decisions, as highlighted in a recent report by the Institute for Clinical and Economic Review (ICER). This call for reform emerges amid growing concerns over the reliability of accelerated approvals, which have been criticized…

Ongoing Cases